PureTech Health (GB:PRTC) has released an update.
Seaport Therapeutics, recently launched by PureTech Health with a $100 million Series A financing, strengthens its leadership by appointing industry veteran Denice Torres to its Board and Eric Green as COO, alongside Co-founder Michael Chen as CSO. These strategic moves aim to advance Seaport’s pipeline of neuropsychiatric medicines, leveraging PureTech’s 61.5% equity ownership post-financing to drive value and innovation. The Glyph platform underpins Seaport’s efforts to develop novel treatments with improved oral bioavailability and reduced side effects for conditions like depression and anxiety.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
